Apoptosis-targeting therapies

Nature Reviews Drug Discovery

Volumn 3, Issue 11, 2004, Pages 905-906

  Melnikova, Irena ^a   Golden, James ^a  

^a Life Science Insights   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ADVEXIN; BEVACIZUMAB; BORTEZOMIB; CASPASE INHIBITOR; CEP 1347; CETUXIMAB; DACARBAZINE; ENZYME ACTIVATOR; GEFITINIB; HUMAN MONOCLONAL ANTIBODY; IDN 6734; IMATINIB; INHIBITOR OF APOPTOSIS PROTEIN; MONOCLONAL ANTIBODY; NGN 201; OBLIMERSEN; ONYX 015; PROTEASOME; PROTEIN INHIBITOR; PROTEIN KINASE; PROTEIN P53; SCH 58500; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; CARCINOGENICITY; CELL COUNT; CELL LOSS; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG MECHANISM; DRUG RESISTANCE; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; HUMAN; MELANOMA; MULTIPLE MYELOMA; NOTE; PRIORITY JOURNAL;

APOPTOSIS; DRUG DESIGN; DRUG INDUSTRY;

EID: 8844270179     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1554     Document Type: Note

References (3)

1. Alam, J. J. Apoptosis: target for novel drugs. Trends Biotechnol. 21, 479-483 (2004).
2. Debatin, K. M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol. Immunother. 53, 153-159 (2004).
3. Mitchell, S. B. The proteasome - an emerging therapeutic target in cancer. N. Engl. J. Med. 348, 2597-2598 (2003).